September 2023 in “Journal of the American Academy of Dermatology” This study found that the incidence of major adverse cardiovascular events in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis who received Ixekizumab was low and stable over 3 to 5 years across 25 clinical trials.
19 citations
,
March 2018 in “Expert Opinion on Drug Safety” In this narrative review, the researchers reported that the overall safety profile of drugs used for treating spondyloarthritis is generally good, with serious adverse events being rare, but emphasized the need for rheumatologists to tailor treatments and closely monitor patients for potential adverse events.
February 2024 in “Curēus” In this case report, secukinumab therapy for spondyloarthritis was associated with the development of alopecia areata in a 46-year-old woman, which improved after discontinuing the medication.
78 citations
,
January 2013 in “Dermatology Online Journal” This review discusses various diseases associated with hidradenitis suppurativa, including obesity, arthritis, and pyoderma gangrenosum, but reports no new clinical results and calls for further research.
223 citations
,
September 2018 in “Rheumatology” This review examines clinical data on the efficacy and safety of JAK inhibitors used for immune-mediated conditions beyond rheumatoid arthritis, highlighting their potential therapeutic roles in various inflammatory diseases.